Keros Therapeutics, Inc. (NASDAQ:KROS) Given Consensus Recommendation of “Buy” by Brokerages
Shares of Keros Therapeutics, Inc. (NASDAQ:KROS – Get Free Report) have been given an average recommendation of “Buy” by the six analysts that are currently covering the stock, Marketbeat reports. Six equities research analysts have rated the stock with a buy recommendation. The average 12-month price target among brokerages that have updated their coverage on […]
More Stories
Iran Protest Death Toll Nears 4,000, Human Rights Group Says
By Guy Birchall The U.S.-based Human Rights Activists News Agency (HRANA) said on Jan. 18 that it estimates at least...
All of Us Are Dead Season 2: Release Date, Cast, Trailer, and Updates
The Korean drama “All of Us Are Dead” was first released on January 28, 2022. Upon its release, the series...
Who is Milo Manheim Dating? Know About the ‘Tangled’ Lead Character
Milo Manheim, the actor, rose to fame from the Zombies franchise on Disney television films. His other films, like Journey...
Kathryn Morris Net Worth, Career, and Life After Cold Case
Starting from a simple life to becoming a name that everyone knows and remembers, Kathryn Morris has come a long way....
Gmail Introduces One of the Biggest Changes Since Its Launch Decades Ago!
Google has completely integrated its Gemini AI into Gmail, launching new features like AI-powered email summaries, personalized replies, and a...
EU Hosts Emergency Meeting in Response to Trump’s Tariffs Over Greenland
By Jacob Burg The European Union called an emergency meeting of ambassadors from the bloc’s 27 nations on Jan. 18...